SynthesisArchives of dermatological research2024
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in psoriasis: a systematic review and meta-analysis.
Synthesis in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Associations of novel complete blood count-derived inflammatory markers with psoriasis: a systematic review and meta-analysis.Archives of dermatological research · 2024Pooled it
- Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Psoriatic Arthritis: A DAPSA-Based Validation Study.Mediterranean journal of rheumatology · 2026Article
- The Role of Immature Granulocyte Count and Percentage as Novel Indicators of Systemic Inflammation in Plaque Psoriasis.Journal of clinical medicine · 2026Article
- Value of Blood Count-Derived Inflammatory Markers for Evaluating Psoriasis Severity: Pilot Cross-Sectional Observational Study.Interactive journal of medical research · 2026Article
- Neutrophil-to-Lymphocyte Ratio as a Predictor of Cardiovascular Events in Psoriatic Disease: A Retrospective Cohort Study.ACR open rheumatology · 2026Article
- Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis.Journal of clinical medicine · 2026Article
- Elevated neutrophil-to-lymphocyte ratio and the incidence of autoimmune diseases: evidence from a large prospective cohort study.Scientific reports · 2026Article
- Predictive Factors of Early Super-Response to Biologic Agents in Psoriasis: Insights from Real-World Evidence.Clinical, cosmetic and investigational dermatology · 2026Article
- Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.Dermatology practical & conceptual · 2025Article
- A Cross-Sectional Study of Platelet-to-Lymphocyte Ratio in Relation to Pigment Cell Nevi and Atypical Mole Syndrome.Health science reports · 2025Article
- The Relationship Between Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index Markers and Response to Biological Therapy in Patients with Psoriasis.International journal of molecular sciences · 2025Article
- Are IL-17 inhibitors superior to IL-23 inhibitors in reducing systemic inflammation in moderate-to-severe plaque psoriasis? A retrospective cohort study.Archives of dermatological research · 2025Observational
- Real-World Experience of Guselkumab in the Elderly Population.Psoriasis (Auckland, N.Z.) · 2025Article
- Evaluation of Pan-Immune-Inflammation Value (PIV) as a Predictive Biomarker for Psoriatic Arthritis in Patients with Psoriasis.Clinical, cosmetic and investigational dermatology · 2025Article
- Clinical significance of blood cell ratios in healthy and sick Leishmania infantum-seropositive dogs.Parasites & vectors · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
Psoriasis is a chronic, inflammatory skin disorder characterized by well-demarcated erythematous lesions with surface scaling. The disease is underpinned by a dysregulated immune response with a shift in the balance of neutrophils, lymphocytes and platelets. We sought to evaluate the novel systemic inflammatory markers, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as psoriatic indicators. Pubmed, Web of Science and Scopus were systematically searched for relevant studies. Twenty-four studies consisting of a total of 2,275 psoriatic patients (1,301 males and 974 females) and 2,334 healthy controls (1,401 males and 933 females) were identified for inclusion in the quantitative analysis. The NLR and PLR were found to be significantly increased in psoriatic patients [standardized mean difference (SMD) = 0.68, 95% CI 0.56-0.80, p < 0.01, and SMD = 0.37, 95% CI 0.14-0.60, p < 0.01, respectively]. However, no association between the NLR and PLR with psoriasis severity was detected (p = 0.93, and p = 0.83, respectively). In conclusion, the NLR and PLR are simple and cost-effective markers of psoriatic presence, but their value as severity markers requires further study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.